Search
Mirikizumab
go.drugbank.com/drugs/DB14910ApprovedInvestigationalMirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. … [L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the EMA's Committee for Medicinal Products for Human Use in March 2023.
Products: Misuvya 100 mg/1 mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem, 2 ADET, Misuvya 100 mg/1 mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem, 6 ADETAgrostis gigantea pollen
go.drugbank.com/drugs/DB10403ApprovedAgrostis gigantea pollen is the pollen of the Agrostis gigantea plant. Agrostis gigantea pollen is mainly used in allergenic testing.
Mixtures: GRASS MIX Number 4-S, GRASS MIX Number 4-SLactitol
go.drugbank.com/drugs/DB12942ApprovedLactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. … [A190918] It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]).
Categories: Compounds used in a research, industrial, or household settingPhenazopyridine
go.drugbank.com/drugs/DB01438ApprovedInvestigationalPhenazopyridine, also known as Pyridium, is a urinary tract analgesic used for the short-term management of urinary tract irritation and its associated unpleasant symptoms such as burning and pain during … [L7832] It is still used in various parts of the world. Ingestion of phenazopyridine is found to change the appearance of the urine by imparting an orange or red color, as it is considered an azo dye.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 2,6-Diamino-3-phenylazopyridine, 2,6-Diamino-3-(phenylazo)pyridineGivosiran
go.drugbank.com/drugs/DB15066ApprovedGivosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. … [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder
Categories: Heterocyclic Compounds, 1-Ring, Aminolevulinate Synthase 1-directed RNA InteractionRelugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigationalRelugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. … administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesRolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalNeurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). … Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration
Categories: Substance P/Neurokinin-1 Receptor Antagonist, Neurokinin 1 AntagonistsValbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigationalValbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's … The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: REMLEAS™ hard capsules 40mgHuman calcitonin
go.drugbank.com/drugs/DB06773Approved[A32099] It is constituted as a 32-amino acid single chain polypeptide structure that gets secreted as a regulatory agent in calcium-phosphorus metabolism. … [A32098] It is used as an alternative for people developing antibodies against salmon calcitonin.[A32100]
Istradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigational[A184067] This region of the brain is highly involved in motor control.[A184067] Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease. … [A184067] Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia.
Categories: MATE 1 Inhibitors, MATE 2 Inhibitors